DX 9065a

Drug Profile

DX 9065a

Latest Information Update: 19 Oct 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Daiichi Sankyo Company; Duke University Medical Center
  • Class Naphthalenes; Propionic acids
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Acute coronary syndromes; Coronary artery restenosis; Disseminated intravascular coagulation; Thrombosis

Most Recent Events

  • 15 May 2008 Discontinued - Phase-II for Disseminated intravascular coagulation in Japan (PO)
  • 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
  • 15 Dec 2003 Data presented at the 45th Annual Meeting of the American Society of Hematology (ASH-2003) have been added to the pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top